Pre-clinical study with Lanifibranor – Prof Gracia-Sancho

Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.
Play Video

Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.

Several strategies are available for detecting cirrhosis in patients with NAFLD, but their cost effectiveness is not clear.

Prof. Gracia Sancho

Prof. Gracia Sancho

SUBSCRIBE & FOLLOW US

Subscribe Our Newsletter To Get the Lastest Updates